SKP2 and cancer: Similarly, amplification and overexpression of SKP2 promotes the increased degradation of P27 and disease progression [56] and is associated with worse survival outcomes and poor response to therapy in numerous cancer types [87,88,89], contributing to SKP2 being traditionally classified as an oncogene.